natgillin/translations-raw huggingface dataset:
For the treatment of ITP in adults, Revolade was compared with placebo (a dummy treatment) in two main studies involving a total of 311 patients who had previously been treated, but the treatments had not worked or the disease had come back.
Za zdravljenje imunske trombocitopenične purpure pri odraslih so zdravilo Revolade primerjali s placebom (zdravilom brez učinkovine) v dveh glavnih študijah, ki sta vključevali skupno 311 predhodno zdravljenih bolnikov, pri katerih zdravljenje ni delovalo ali pa se je bolezen ponovila.
For the full list of restrictions and side effects of Revolade, see the package leaflet.
Za celoten seznam omejitev in neželenih učinkov zdravila Revolade glejte navodilo za uporabo.
Important serious side effects are liver problems and thromboembolic complications.
Pomembni resni neželeni učinki so težave z jetri in trombembolični zapleti.
Revolade was more effective than placebo: in the first study, 59% of the patients who took Revolade (43 out of 73) achieved a platelet count of at least 50,000 per microlitre (which is considered adequate to prevent bleeding complications) after 6 weeks of treatment, compared with 16% of those who took placebo (6 out of 37).
Zdravilo Revolade je bilo učinkovitejše od placeba: v prvi študiji je število trombocitov pri 59 % (43 od 73) bolnikov, ki so jemali zdravilo Revolade, po šestih tednih zdravljenja doseglo vsaj 50 000 trombocitov na mikroliter (kar šteje kot zadostno za preprečevanje zapletov s krvavitvami), pri bolnikih, ki so jemali placebo, pa je bilo takšnih 16 % (6 od 37).
• primary immune thrombocytopenia (ITP), a disease in which the patient's immune system destroys platelets (components in the blood that help it to clot).
• primarne imunske trombocitopenične purpure, tj. bolezni, pri kateri bolnikov imunski sistem uničuje trombocite (sestavino krvi, ki sodeluje pri njenem strjevanju).
These compared Revolade with placebo for allowing the starting and maintenance of antiviral treatment in patients with hepatitis C whose platelet count was initially too low to allow starting such treatment (less than 75,000 per microlitre).
V okviru teh študij so zdravilo Revolade primerjali s placebom, da bi ugotovili, ali omogoča začetno in vzdrževalno protivirusno zdravljenje pri bolnikih s hepatitisom C, katerih število trombocitov je bilo ob začetku zdravljenja prenizko, da bi lahko pri njih uvedli tovrstno terapijo (nižje od 75 000 na mikroliter).
The main measure of effectiveness was the number of patients who responded to Revolade (whose platelet, red or white blood cell count remained above pre-set levels) after 12 or 16 weeks of treatment.
Glavno merilo učinkovitosti je bilo število bolnikov, ki so se po 12 ali 16 tednih zdravljenja odzvali na zdravilo Revolade (pri katerih je število trombocitov ter rdečih in belih krvnih celic ostalo nad predhodno določenimi ravnmi).
The most important serious side effects are liver problems and thromboembolic complications (problems with clots in blood vessels).
Najpomembnejši resni neželeni učinki so težave z jetri in trombembolični zapleti (težave s strdki v krvnih žilah).
The most common side effects with Revolade in adults with ITP (which may affect more than 1 in 10 people) are nausea (feeling sick), diarrhoea and abnormal blood levels of certain liver enzymes.
Najpogostejši neželeni učinki zdravila Revolade pri odraslih z imunsko trombocitopenično purpuro (ki lahko prizadenejo več kot 1 osebo od 10) so navzeja (slabost), driska in nenormalne ravni nekaterih jetrnih encimov v krvi.
How is Revolade used?
Kako se zdravilo Revolade uporablja?
How does Revolade work?
Kako zdravilo Revolade deluje?
The active substance in Revolade, eltrombopag, also attaches to and stimulates the thrombopoietin receptors.
Učinkovina v zdravilu Revolade, eltrombopag, se tudi veže na receptorje trombopoetina in v njih povzroči enak spodbujevalni učinek.
This study lasted 13 weeks and looked at the proportion of patients whose platelet count had increased to at least 50,000 per microlitre for at least 6 out of 8 weeks, between week 5 to 12 of the study in the absence of rescue medication.
V študiji, ki je trajala 13 tednov, so proučevali delež bolnikov, pri katerih se je število trombocitov povečalo za vsaj 50 000 na mikroliter v najmanj šestih tednih od osmih med petim in dvanajstim tednom študije brez olajševalnega zdravila.
In the body, a hormone called ‘thrombopoietin' stimulates the production of platelets by attaching to certain receptors (targets) in the bone marrow.
V telesu nastajanje trombocitov spodbuja hormon trombopoetin, tako da se veže na določene receptorje (prijemališča) v kostnem mozgu.
This occurred in around 40% of those taking Revolade (25 out of 63) compared with around 3% (1 out of 29) of those who took placebo.
Do tega je prišlo pri približno 40 % (25 od 63) bolnikov, ki so jemali zdravilo Revolade, pri tistih, ki so jemali placebo, pa pri približno 3 % (pri 1 od 29).
In patients with thrombocytopenia and advanced chronic hepatitis C who are treated with interferon and Revolade, the most common side effects include headache, anaemia (low red blood cell counts), decreased appetite, cough, nausea, diarrhoea, high levels of bilirubin in the blood, hair loss, itching, muscle pain, fever, tiredness, flu-like illness, weakness, chills and swelling (because of build-up of water in the body).
Pri bolnikih s trombocitopenijo in napredovalim kroničnim hepatitisom C, ki se zdravijo z interferonom in zdravilom Revolade, so najpogostejši neželeni učinki glavobol, anemija (nizko število rdečih krvnih celic), zmanjšan tek, kašelj, siljenje na bruhanje, driska, visoke ravni bilirubina v krvi, izpadanje las, srbenje, bolečine v mišicah, povišana telesna temperatura, utrujenost, gripi podobna bolezen, šibkost, mrzlica in otekanje (zaradi kopičenja vode v telesu).
In children with ITP, Revolade was more effective than placebo in one main study involving 92 children between 1 and 17 years of age who had previously been treated for ITP.
Pri otrocih z imunsko trombocitopenično purpuro je bilo v eni glavni študiji, ki je vključevala 92 predhodno zdravljenih otrok, starih od enega do 17 let, zdravilo Revolade učinkovitejše od placeba.
The dose depends on the patient's age and the disease for which Revolade is being used; it is adjusted as needed to maintain the appropriate platelet level.
Odmerek je odvisen od starosti bolnika in bolezni, za katero se zdravilo Revolade uporablja.
In this study, 40% of patients (17 out of 43) responded to treatment after 12 weeks, and in 65% of them (11 out of 17) the platelet count either increased by at least 20,000 per microliter or it was stable without a need for blood transfusions.
Pri 65 % (11 od 17) vseh, ki so se odzvali, se je število trombocitov bodisi povečalo za vsaj 20 000 na mikroliter bodisi je bilo stabilno, ne da bi bila potrebna transfuzija krvi.
In adults with severe aplastic anaemia the most common side effects include headache, dizziness, cough, pain in the belly or in the mouth and throat, nausea, diarrhoea, joint pain, pain in limbs, tiredness, fever and abnormal blood levels of certain liver enzymes.
Pri odraslih z resno aplastično anemijo so najpogostejši neželeni učinki glavobol, omotica, kašelj, bolečina v trebuhu ali v ustih in žrelu, siljenje na bruhanje, driska, bolečine v sklepih, bolečine v udih, utrujenost, povišana telesna temperatura in nenormalne ravni nekaterih jetrnih encimov v krvi.
Patients should not take medicines such as antacids or dairy products and mineral supplements in the 4 hours before and in the 2 hours after taking Revolade.
Štiri ure pred jemanjem zdravila Revolade in dve uri po njem bolniki ne smejo zaužiti antacidov, mlečnih izdelkov ali mineralnih prehranskih dopolnil.
Patients with ITP have low platelet counts in the blood (thrombocytopenia) and are at risk of bleeding.
Bolniki z imunsko trombocitopenično purpuro imajo nizko število trombocitov v krvi (trombocitopenijo) in povečano tveganje za krvavitve.
In the second study, patients taking Revolade were around 8 times more likely than those taking placebo to reach the target platelet count of between 50,000 and 400,000 per microlitre during the 6 months of treatment.
V drugi študiji je bila pri bolnikih, ki so jemali zdravilo Revolade, verjetnost, da dosežejo ciljno število trombocitov med 50 000 in 400 000 na mikroliter v šestih mesecih zdravljenja, približno osemkrat večja kot pri skupini, ki je jemala placebo.
In children with ITP, the most common side effects include nose and throat infection, cough, fever, pain in the belly or in the mouth and throat, toothache and runny nose.
Pri otrocih z imunsko trombocitopenično purpuro so najpogostejši neželeni učinki okužbe nosu in grla, kašelj, povišana telesna temperatura, bolečina v trebuhu ali v ustih in žrelu, zobobol in izcedek iz nosu.
• thrombocytopenia in adults with chronic (long-term) hepatitis C, a liver disease caused by the hepatitis C virus.
• trombocitopenije pri odraslih s kroničnim (dolgotrajnim) hepatitisom C, tj. boleznijo jeter, ki jo povzroča okužba z virusom hepatitisa C. Zdravilo Revolade se uporablja, kadar je trombocitopenija prehuda, da bi dovoljevala zdravljenje z interferonom (vrsto zdravljenja hepatitisa C);
This increases the production of platelets, improving platelet counts.
Zato začne nastajati več trombocitov, kar poveča njihovo raven.
if you are more than 3 months pregnant.
če ste noseči več kot 3 mesece.
In some cases you may have to stop taking one of the medicines.
V nekaterih primerih boste morda morali nehati jemati eno od teh zdravil.
Date of first authorisation: 16 January 2007 Date of latest renewal: 21 November 2011
Datum prve odobritve: 16. januar 2007 Datum zadnjega podaljšanja: 21. november 2011
Elderly (age 65 years or over)
Starejši (starost 65 let in več)
It is preferable to take your medicine at the same time each day.
Zaželeno je, da vzamete zdravilo vsak dan ob istem času.
If you forget to take this medicine, take it as soon as you remember.
Če ste pozabili vzeti zdravilo, ga vzemite, takoj ko se spomnite.
Your doctor may need to change your dose and/or to take other precautions.
Zdravnik vam bo morda moral spremeniti odmerek in/ali upoštevati druge previdnostne ukrepe.
• Shock (including cardiogenic shock).
• Šok (vključno s kardiogenim šokom).
if you are taking any of the following medicines used to treat high blood pressure:
če jemljete katero od naslednjih zdravil, ki se uporabljajo za zdravljenje visokega krvnega tlaka:
Do not exceed the prescribed dose.
Ne prekoračite predpisanega odmerka.
D-90429 Nuremberg Germany
D-90429 Nürnberg Nemčija
Then take your next dose at its usual time.
Naslednji odmerek nato vzemite ob običajnem času.
So, if you are not sure how this medicine will affect you, do not drive, use machinery, or do other activities that you need to concentrate on.
Če niste prepričani, kako bo to zdravilo vplivalo na vas, ne upravljajte vozil, ne uporabljajte orodja ali strojev in ne izvajajte drugih dejavnosti, ki zahtevajo koncentracijo.
This can affect how well you can concentrate.
Vpliva lahko na vašo sposobnost koncentracije.
(It is also better to avoid Dafiro in early pregnancy, see Pregnancy section).
(Zdravilu Dafiro se je bolje izogibati tudi v zgodnji nosečnosti, glejte poglavje Nosečnost).
Stevens-Johnson syndrome
Stevens-Johnson sindrom -
Rare (may affect up to 1 in 1,000 people): Confusion.
Redki (pojavijo se pri do 1 od 1.000 ljudi): zmedenost.
In two long-term follow-up studies the effect of Dafiro was maintained for over one year.
V dveh dolgoročnih spremljevalnih študijah se je učinek zdravila Dafiro ohranil več kot eno leto.
if you have severe low blood pressure (hypotension).
če imate zelo znižan krvni tlak (hipotenzijo).
A total of 33,357 hypertensive patients aged 55 or older were randomised and followed for a mean of 4.9 years.
Skupno so randomizirali 33.357 hipertenzivnih bolnikov, starih 55 let ali več, in jih spremljali povprečno 4,9 leta.
Novartis Farmacéutica SA Ronda de Santa Maria 158 08210 Barberà del Vallès, Barcelona Spain
Novartis Farmacéutica SA Ronda de Santa Maria 158 08210 Barberà del Vallès, Barcelona Španija
- Swelling of the tongue and throat which causes great difficulty breathing.
- otekanje jezika in grla, ki zelo oteži dihanje.
If any of these cause you problems or if they last for more than one week, you should contact your doctor.
Če vam katerikoli od teh povzroča težave ali traja dlje kot 1 teden, pokličite svojega zdravnika.
However, if it is almost time for your next dose, skip the dose you missed.
Če pa je že skoraj čas za naslednji odmerek, preskočite izpuščeni odmerek.
Age, gender, race or body mass index (≥30 kg/m 2, <30 kg/m 2) did not influence the response to
Starost, spol, rasa ali indeks telesne mase (≥30 kg/m 2, <30 kg/m 2) niso vplivali na odziv na zdravilo
The proportion of the maternal dose received by the infant has been estimated with an interquartile range of 3-7%, with a maximum of 15%.
Ocenjujejo, da je delež materinega odmerka, ki ga prejme otrok, v interkvartilnem razponu 3-7 %, najvišji delež pa je 15 %.
Approximate size: diameter 8.20 mm.
Približna velikost: premer 8,20 mm.
There were only modest signs of maternal toxicity (moderate reduction of body weight) in this study.
Znaki toksičnih učinkov pri materi (zmerno zmanjšanje telesne mase) so bili v tej študiji le skromni.
See also information under the heading “Do not take Dafiro”.
Glejte tudi informacije pod naslovom “Ne jemljite zdravila Dafiro”.
Both of these substances help to control high blood pressure.
Obe pomagata obvladovati visok krvni tlak.
Paediatric population (age below 18 years) No pharmacokinetic data are available in the paediatric population.
Pediatrična populacija (starost do 18 let) Farmakokinetičnih podatkov za pediatrično populacijo ni.
Your doctor may also check your kidney function.
Zdravnik bo morda pregledal tudi delovanje vaših ledvic.
• Second and third trimesters of pregnancy (see sections 4.4 and 4.6).
• Drugo in tretje trimesečje nosečnosti (glejte poglavji 4.4 in 4.6).
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
Od zdravstvenih delavcev se zahteva, da poročajo o katerem koli domnevnem neželenem učinkuzdravila na nacionalni center za poročanje, ki je naveden v Prilogi V.
The antihypertensive effect of a single dose of the combination persisted for 24 hours.
Antihipertenzivni učinek enega odmerka kombinacije je trajal 24 ur.
Depending on how you respond to the treatment, your doctor may suggest a higher or lower dose.
Glede na vaš odziv na zdravilo vam bo zdravnik nato morda svetoval večji ali manjši odmerek.
Do not use this medicine after the expiry date which is stated on the carton and blister.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in pretisnem omotu.
Dafiro and older people (age 65 years or over) Your doctor should exercise caution when increasing your dose.
Zdravilo Dafiro in starejši ljudje (stari 65 let ali več) Zdravnik mora biti pri zviševanju vašega odmerka previden.
• Severe hypotension.
• Huda hipotenzija.
Approximate size: 14.2 mm (length) x 5.7 mm (width).
Približna velikost: 14,2 mm (dolžina) x 5,7 mm (širina).
Dafiro with food and drink
Zdravilo Dafiro skupaj s hrano in pijačo
Valsartan is highly bound to serum proteins (94-97%), mainly serum albumin.
Valsartan je močno vezan na beljakovine v serumu (94-97 %), predvsem na albumin v serumu.
Elimination: Valsartan shows multiexponential decay kinetics (t½α <1 h and t½ß about 9 h).
Izločanje: Valsartan kaže multieksponentno kinetiko upadanja (t½α <1 uro in t½ß približno 9 ur).
Follow your doctor's instructions for the starting dose carefully.
Natančno se držite zdravnikovih navodil glede začetnega odmerka.
Your doctor will normally advise you to stop taking Dafiro before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Dafiro.
Zdravnik vam bo praviloma svetoval, da prenehate z jemanjem zdravila Dafiro še preden zanosite oziroma takoj, ko ugotovite da ste noseči in vam bo svetoval jemanje drugega zdravila namesto zdravila Dafiro.
It is recommended to take Dafiro with some water.
Zdravilo Dafiro je priporočljivo vzeti z malo vode.
Mean systemic AUC of valsartan is higher by 70% in the elderly than in the young therefore caution is required when increasing the dosage.
Povprečna sistemska AUC valsartana je pri starejših za 70 % večja kot pri mladih, zato je pri večanju odmerka potrebna previdnost.
In double-blind, controlled clinical trials, the incidence of peripheral oedema by dose was as follows:
V dvojno slepih, kontroliranih kliničnih preskušanjih je bila incidenca perifernih edemov glede na odmerke sledeča:
Dafiro is not recommended in early pregnancy (first 3 months), and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.
Jemanje zdravila Dafiro v zgodnjem obdobju nosečnosti (v prvih 3 mesecih) ni priporočljivo, če pa ste noseči več kot 3 mesece, ga ne smete jemati, ker lahko uporaba po tretjem mesecu nosečnosti povzroči resno škodo vašemu otroku.
Use in patients with hypertension
Uporaba pri bolnikih s hipertenzijo
Valsartan is primarily eliminated in faeces (about 83% of dose) and urine (about 13% of dose), mainly as unchanged drug.
Valsartan se v prvi vrsti izloči v blato (okrog 83 % odmerka) in urinu (okrog 13 % odmerka), v glavnem v obliki nespremenjenega zdravila.
The safety of Dafiro has been evaluated in five controlled clinical studies with 5,175 patients, 2,613 of whom received valsartan in combination with amlodipine.
Varnost zdravila Dafiro so ocenjevali v petih kontroliranih kliničnih študijah s 5.175 bolniki, od katerih jih je 2.613 prejemalo valsartan v kombinaciji z amlodipinom.
if you have a condition affecting the renal glands called “primary hyperaldosteronism”.
če imate posebno bolezen nadledvičnih žlez, imenovano “primarni hiperaldosteronizem”.
- Swelling of eyelids, face or lips.
- otekanje očesnih vek, obraza ali ustnic.
Patients taking Dafiro and driving vehicles or using machines should take into account that dizziness or weariness may occasionally occur.
Bolniki, ki jemljejo zdravilo Dafiro in vozijo motorna vozila ali uporabljajo stroje, morajo upoštevati, da se lahko občasno pojavi omotica ali utrujenost.
Adverse reactions have been ranked under headings of frequency using the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data).
Neželeni učinki so razvrščeni po oznakah pogostnosti upoštevaje naslednji dogovor: zelo pogosti (≥1/10), pogosti (≥1/100 do <1/10), občasni (≥1/1.000 do <1/100), redki (≥1/10.000 do <1/1.000), zelo redki (<1/10.000), neznana (ni mogoče oceniti iz razpoložljivih podatkov).
Dual blockade of the renin-angiotensin-aldosterone system (RAAS)
Dvojno zaviranje sistema renin-angiotenzin-aldosteron (RAAS)
Do not take Dafiro if you are allergic to amlodipine or to any other calcium channel blockers.
Ne jemljite zdravila Dafiro če ste alergični na amlodipin ali na katerikoli zaviralec kalcijevih kanalčkov.
Amlodipine (mg)
amlodipin (mg)
Amlodipine can have mild or moderate influence on the ability to drive and use machines.
Amlodipin ima lahko blag do zmeren vpliv na sposobnost vožnje in upravljanja s stroji.
Concomitant use not recommended
Sočasna uporaba ni priporočena
Children and adolescents The use of Dafiro in children and adolescents is not recommended (aged below 18 years old).
Otroci in mladostniki Zdravila Dafiro ni priporočljivo uporabljati pri otrocih in mladostnikih (starih manj kot 18 let).
Amlodipine/Valsartan
Amlodipin/valsartan
• Obligation to conduct post-authorisation measures The MAH shall complete, within the stated timeframe, the below measures:
• Obveznost izvedbe ukrepov po pridobitvi dovoljenja za promet Imetnik dovoljenja za promet z zdravilom mora v določenem časovnem okviru izvesti naslednje ukrepe:
What Dafiro is and what it is used for
Kaj je zdravilo Dafiro in za kaj ga uporabljamo
Marked and potentially prolonged systemic hypotension up to and including shock with fatal outcome have been reported.
Poročali so o izraziti in potencialno dolgotrajni sistemski hipotenziji vse do šoka, tudi takšnega s smrtnim izidom.
Patients with hepatic impairment have decreased clearance of amlodipine with resulting increase of approximately 40-60% in AUC.
Bolniki z okvaro jeter imajo znižan očistek amlodipina; posledica je zvišanje AUC za približno 40-60 %.
The safety and efficacy of amlodipine in hypertensive crisis have not been established.
Varnost in učinkovitost amlodipina pri hipertenzivni krizi nista bili ugotovljeni.
Interactions linked to amlodipine
Interakcije, povezane z amlodipinom
Do not stop taking your medicine unless your doctor tells you to.
Ne prenehajte jemati zdravila, če vam ni tako naročil zdravnik.
During repeated administration, the maximum reduction in blood pressure with any dose is generally attained within 2-4 weeks and is sustained during long-term therapy.
Med večkratno uporabo je največje znižanje krvnega tlaka pri vseh odmerkih praviloma doseženo v 2 do 4 tednih in se med dolgotrajnim zdravljenjem ohrani.
In elderly patients, caution is required when increasing the dosage.
Pri starejših bolnikih je treba odmerjanje povečevati previdno.
Valsartan is mostly eliminated unchanged via the bile.
Valsartan se večinoma izloči nespremenjen v žolču.
The combination of these substances has an additive antihypertensive effect, reducing blood pressure to a greater degree than either component alone.
Kombinacija teh dveh učinkovin ima aditiven antihipertenziven učinek in znižuje krvni tlak v večji meri kot vsaka sestavina zase.
if you have narrowing of the aortic valve (aortic stenosis) or cardiogenic shock (a condition where your heart is unable to supply enough blood to the body).
če imate zoženje aortne zaklopke (aortno stenozo) ali kardiogeni šok (stanje, v katerem srce ne more črpati dovolj močno, da bi oskrbelo telo s krvjo).
As a result, the blood vessels relax and blood pressure is lowered.
Zato se žile sprostijo in krvni tlak se zniža.
This may involve itching, reddening of the skin or difficulty in breathing.
To lahko vključuje srbenje, rdečino kože ali oteženo dihanje.
Interactions linked to valsartan
Interakcije, povezane z valsartanom
if you have liver or kidney problems.
če imate težave z jetri ali ledvicami.
an ACE inhibitor (for example enalapril, lisinopril, ramipril), in particular if you have diabetes-related kidney problems.
zaviralec ACE (na primer enalapril, lizinopril ali ramipril), zlasti če imate kakšne težave z ledvicami, ki so povezane s sladkorno boleznijo.
The safety and efficacy of Dafiro in children aged below 18 years have not been established.
Varnost in učinkovitost zdravila Dafiro pri otrocih, starih manj kot 18 let, nista bili dokazani.
The following side effects have been reported.
Poročali so o naslednjih neželenih učinkih.
As with all other vasodilators, special caution is indicated in patients suffering from mitral stenosis or significant aortic stenosis that is not high grade.
Tako kot pri vseh vazodilatatorjih, je posebna previdnost potrebna pri bolnikih z mitralno stenozo ali s pomembno aortno stenozo, ki sicer ni močno izražena.
To date there is no experience of the safe use of Dafiro in patients who have had a recent kidney transplantation.
Doslej ni izkušenj glede varnosti uporabe zdravila Dafiro pri bolnikih, ki jim je bila nedavno presajena ledvica.
Evaluation of patients with heart failure or post-myocardial infarction should always include assessment of renal function.
Pregled bolnikov, ki imajo srčno popuščanje ali so v obdobju po miokardnem infarktu, mora vedno vključevati oceno ledvične funkcije.
Elimination: Amlodipine elimination from plasma is biphasic, with a terminal elimination half-life of approximately 30 to 50 hours.
Izločanje: Eliminacija amlodipina iz plazme je dvofazna s terminalnim razpolovnim časom eliminacije približno 30 do 50 ur.